Correlations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia

다국어 초록 (Multilingual Abstract)

Background: In treatment of pneumonia, microorganisms sometimes persist, appear or reappear despite good clinical responses.
On the other hand, recent increasing antibiotic resistance emphases the goal of rapid eradication of pathogen in severe infection.
This study was planned to evaluate the correlations between microbiological outcomes and clinical responses in severe pneumonia.
Materials and Methods: Data was gathered from 3 clinical trials regarding severe pneumonia. Microbiological outcomes, determined by serial culture of respiratory tract samples,were compared with clinical outcomes.
Results: In total, 146 bacterial strains from 76 patients were analyzed. While clinical success was generally related to total or partial eradication of isolated organisms, Acinetobacter , Enterobacter , Pseudomonas aeruginosa , and Stenotrophomonas maltophilia were often not eradicated and yet were observed in 56% of cases considered clinically successful at the end of antibiotic treatment. Most of the non-eradicated strains (71%) already had or developed resistance against the antibiotics used for treatment.
Ten patients relapsed during the follow-up period; 7 of these relapses were associated with 10 non-eradicated organisms.
Conclusions: These data raise concern about the pathogenicity of bacteria that persist in the respiratory tract even though good clinical outcomes of pneumonia are achieved, especially when Acinetobacter, Enterobacter , P. aeruginosa , or S. maltophilia were involved. Thus, clinical relapse and development of drug resistance by non-eradicated organisms may be raised.

참고문헌 (Reference)

1 Garau J, "Why do we need to eradicate pathogens in respiratorytract infections" 7 (7): S5-S12, 2003

2 Andersson DI, "The biological cost of antibioticresistance" 2 : 489-493, 1999

3 Fux CA, "Survivalstrategies of infectious biofilms" 13 : 34-40, 2005

4 Wunderink RG, "Surrogate markers and microbiologic endpoints" 51 (51): S126-S130, 2010

5 Fink MP, "Severe Pneumonia Study Group.Treatment of severe pneumonia in hospitalized patients:results of a multicenter, randomized, double-blind trialcomparing intravenous ciprofloxacin with imipenemcilastatin.The Severe Pneumonia Study Group" 38 : 547-557, 1994

6 Forrest A, "Schentag JJ. Pharmacodynamics of intravenous ciprofloxacinin seriously ill patients" 37 : 1073-1081, 1993

7 Kugelberg E, "Reductionof the fitness burden of quinolone resistance inPseudomonas aeruginosa" 55 : 22-30, 2005

8 Ravizzola G, "Reduced virulence in ciprofloxacinresistantvariants of Pseudomonas aeruginosa strains" 20 : 825-829, 1987

9 Garcia-Medina R, "Pseudomonasaeruginosa acquires biofilm-like propertieswithin airway epithelial cells" 73 : 8298-8305, 2005

10 Clark RB, "Phenotypic factors correlatedwith the absence of virulence among gentamicin-resistantPseudomonas aeruginosa strains" 20 : 235-238, 1984

11 Thomas JK, "Pharmacodynamic evaluation offactors associated with the development of bacterial resistancein acutely ill patients during therapy" 42 : 521-527, 1998

12 Andersson DI, "Persistence of antibiotic resistant bacteria" 6 : 452-456, 2003

13 Guillemot D, "Lowdosage and long treatment duration of beta-lactam: riskfactors for carriage of penicillin-resistant Streptococcuspneumoniae" 279 : 365-370, 1998

14 Beam TR Jr, "General guidelines forthe clinical evaluation of anti-infective drug products. InfectiousDiseases Society of America and the Food andDrug Administration" 15 (15): S5-S32, 1992

15 De Lencastre H, "From ecological reservoir todisease: the nasopharynx, day-care centres and drug-resistantclones of Streptococcus pneumoniae" 50 (50): 75-81, 2002

16 Sanchez P, "Fitness of in vitro selected Pseudomonasaeruginosa nalB and nfxB multidrug resistantmutants" 50 : 657-664, 2002

17 Dagan R, "Evidence tosupport the rationale that bacterial eradication in respiratorytract infection is an important aim of antimicrobialtherapy" 47 : 129-140, 2001

18 Chow AW, "Evaluation of new anti-infective drugs forthe treatment of respiratory tract infections. InfectiousDiseases Society of America and the Food and Drug Administration" 15 (15): S62-S88, 1992

19 Ghaffar F, "Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriageof Streptococcus pneumoniae, Haemophilus influenzae,nonpneumococcal alpha-hemolytic streptococci, andStaphylococcus aureus in children with acute otitis media" 34 : 1301-1309, 2002

20 Ghaffar F, "Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media" 31 : 875-880, 2000

21 Schrag SJ, "Effect of short-course, high-doseamoxicillin therapy on resistant pneumococcal carriage: arandomized trial" 286 : 49-56, 2001

22 Dagan R, "Early eradication of pathogens from middleear fluid during antibiotic treatment of acute otitis mediais associated with improved clinical outcome" 17 : 776-782, 1998

23 Ramisse F, "Decreased virulence of a strain of Pseudomonas aeruginosaO12 overexpressing a chromosomal type 1 betalactamasecould be due to reduced expression of cell-tocellsignaling dependent virulence factors" 28 : 241-245, 2000

24 Stratton CW, "Dead bugs don’t mutate: susceptibility issuesin the emergence of bacterial resistance" 9 : 10-16, 2003

25 Prince AS, "Biofilms, antimicrobial resistance, and airwayinfection" 347 : 1110-1111, 2002

26 Di Martino P, "Antibiotic resistanceand virulence properties of Pseudomonas aeruginosastrains from mechanically ventilated patients with pneumonia in intensive care units: comparison withimipenem-resistant extra-respiratory tract isolates fromuninfected patients" 4 : 613-620, 2002

27 Charlson ME, "A newmethod of classifiying prognostic comorbidity in longitudinalstudies: development and validation" 40 : 373-383, 1987